

01-05-06

IFW

EXPRESS MAIL NO.: EV452776878US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Zeldis et al.

Confirmation No.: 2021

Application No: 10/693,794

Group Art Unit: 1644

Filed: October 23, 2003

Examiner: To Be Assigned

For: METHODS OF USING AND  
COMPOSITIONS COMPRISING  
IMMUNOMODULATORY COMPOUND  
FOR TREATMENT, MODIFICATION  
AND MANAGEMENT OF PAIN

Jones Day Docket No.: 9516-076-999  
(CAM No.: 501872-999075)

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Applicants hereby direct the Examiner's attention to references **A118** and **C05** listed on the attached form PTO 1449 entitled "List of References Cited by Applicant." This Information Disclosure Statement supplements the Information Disclosure Statements filed on July 26, 2004, July 28, 2004, November 15, 2004, March 1, 2005, and June 8, 2005.

A copy of reference **C05** is provided herewith. A copy of reference **A118**, which is a United States patent publication, is not submitted herewith pursuant to 37 C.F.R. § 1.98(a)(2)(ii).

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Applicants respectfully request that the Examiner review the

foregoing references and that the references be made of record in the file history of the application.


This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b) before the mailing of the first Office action on the merits. Therefore, no fee is believed to be due. Should any fee be required, however, please charge such fee to Jones Day Deposit Account No. **503013**.

Respectfully submitted,

Date: January 3, 2006

  
\_\_\_\_\_  
Yeaksil Moon (Reg. No.) 52,042  
For: Anthony M. Insogna 35,203  
**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, New York 10017  
(212) 326-3939

Enclosures



**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
9516-076-999	10/693,794

APPLICANT
Jerome B. Zeldis

FILING DATE	GROUP
October 23, 2003	1644

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
A118		2003/0087962	05/08/2003	Demopoulos et al.			
A119							
A120							
A121							
A122							
A123							
A124							
A125							
A126							
A127							
A128							
A129							

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES      NO
	B01						
	B02						
	B03						
	B04						
	B05						
	B06						
	B07						

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

C05	Wagner et al., "Endoneurial injection of TNF-alpha produces neuropathic pain behaviors," Neuroreport, 1996 Nov 25;7(18):2897-901
C06	
C07	

EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.